Nature Communications (Feb 2023)
T cell-independent eradication of experimental glioma by intravenous TLR7/8-agonist-loaded nanoparticles
- Verena Turco,
- Kira Pfleiderer,
- Jessica Hunger,
- Natalie K. Horvat,
- Kianush Karimian-Jazi,
- Katharina Schregel,
- Manuel Fischer,
- Gianluca Brugnara,
- Kristine Jähne,
- Volker Sturm,
- Yannik Streibel,
- Duy Nguyen,
- Sandro Altamura,
- Dennis A. Agardy,
- Shreya S. Soni,
- Abdulrahman Alsasa,
- Theresa Bunse,
- Matthias Schlesner,
- Martina U. Muckenthaler,
- Ralph Weissleder,
- Wolfgang Wick,
- Sabine Heiland,
- Philipp Vollmuth,
- Martin Bendszus,
- Christopher B. Rodell,
- Michael O. Breckwoldt,
- Michael Platten
Affiliations
- Verena Turco
- Clinical Cooperation Unit Neuroimmunology and Brain Tumor Immunology, German Cancer Consortium (DKTK) within the German Cancer Research Center (DKFZ)
- Kira Pfleiderer
- Clinical Cooperation Unit Neuroimmunology and Brain Tumor Immunology, German Cancer Consortium (DKTK) within the German Cancer Research Center (DKFZ)
- Jessica Hunger
- Clinical Cooperation Unit Neuroimmunology and Brain Tumor Immunology, German Cancer Consortium (DKTK) within the German Cancer Research Center (DKFZ)
- Natalie K. Horvat
- Faculty of Biosciences, Heidelberg University
- Kianush Karimian-Jazi
- Neuroradiology Department, University Hospital Heidelberg
- Katharina Schregel
- Neuroradiology Department, University Hospital Heidelberg
- Manuel Fischer
- Neuroradiology Department, University Hospital Heidelberg
- Gianluca Brugnara
- Neuroradiology Department, University Hospital Heidelberg
- Kristine Jähne
- Clinical Cooperation Unit Neuroimmunology and Brain Tumor Immunology, German Cancer Consortium (DKTK) within the German Cancer Research Center (DKFZ)
- Volker Sturm
- Neuroradiology Department, University Hospital Heidelberg
- Yannik Streibel
- Neuroradiology Department, University Hospital Heidelberg
- Duy Nguyen
- Junior Research Group Bioinformatics and Omics Data Analytics, DKFZ
- Sandro Altamura
- Department of Pediatric Oncology, Hematology and Immunology, University Hospital
- Dennis A. Agardy
- Clinical Cooperation Unit Neuroimmunology and Brain Tumor Immunology, German Cancer Consortium (DKTK) within the German Cancer Research Center (DKFZ)
- Shreya S. Soni
- School of Biomedical Engineering, Science and Health Systems, Drexel University
- Abdulrahman Alsasa
- School of Biomedical Engineering, Science and Health Systems, Drexel University
- Theresa Bunse
- Clinical Cooperation Unit Neuroimmunology and Brain Tumor Immunology, German Cancer Consortium (DKTK) within the German Cancer Research Center (DKFZ)
- Matthias Schlesner
- Junior Research Group Bioinformatics and Omics Data Analytics, DKFZ
- Martina U. Muckenthaler
- Department of Pediatric Oncology, Hematology and Immunology, University Hospital
- Ralph Weissleder
- Center for Systems Biology, Massachusetts General Hospital
- Wolfgang Wick
- Clinical Cooperation Unit Neurooncology, DKTK within DKFZ
- Sabine Heiland
- Neuroradiology Department, University Hospital Heidelberg
- Philipp Vollmuth
- Neuroradiology Department, University Hospital Heidelberg
- Martin Bendszus
- Neuroradiology Department, University Hospital Heidelberg
- Christopher B. Rodell
- School of Biomedical Engineering, Science and Health Systems, Drexel University
- Michael O. Breckwoldt
- Clinical Cooperation Unit Neuroimmunology and Brain Tumor Immunology, German Cancer Consortium (DKTK) within the German Cancer Research Center (DKFZ)
- Michael Platten
- Clinical Cooperation Unit Neuroimmunology and Brain Tumor Immunology, German Cancer Consortium (DKTK) within the German Cancer Research Center (DKFZ)
- DOI
- https://doi.org/10.1038/s41467-023-36321-6
- Journal volume & issue
-
Vol. 14,
no. 1
pp. 1 – 15
Abstract
Glioblastoma is a highly aggressive, and also the most common, brain tumour type in adults. Here, the authors generate a nanoparticle encapsulating the TLR7/8 agonist, R848, which induces tumour regression in mice by reprogramming myeloid cells independently of T and NK cells.
